Treatment success in genetic subgroups
| Subgroups of PP population . | Treatment success: DisC, % (n/n) . | Treatment success: RIST, % (n/n) . | Difference (%) (95% CI) . | P value∗ . |
|---|---|---|---|---|
| All | 84.1 (116/138) | 81.3 (109/134) | 2.7 (−6.3 to 11.8) | .047 |
| ELN 2022 | ||||
| Favorable | 95.5 (21/22) | 100.0 (19/19) | −4.5 (−13.7 to 4.6) | .46 |
| Intermediate | 81.6 (40/49) | 83.3 (60/72) | −1.7 (−15.8 to 12.4) | .32 |
| Adverse | 82.1 (55/67) | 69.8 (30/43) | 12.3 (−3.6 to 28.2) | .016 |
| Genetic abnormality | ||||
| Mutated NPM1 | 95.5 (21/22) | 79.2 (19/24) | 16.3 (−4.2 to 36.8) | .021 |
| Mutated NPM1 and FLT3 wild type | 92.9 (13/14) | 83.3 (10/12) | 9.5 (−15.8 to 34.9) | .13 |
| FLT3-ITD | 95.8 (23/24) | 66.7 (14/21) | 29.2 (6.2 to 52.2) | .0018 |
| Secondary-type mutations† | 90.9 (20/22) | 86.4 (19/22) | 4.5 (−14.7 to 23.8) | .17 |
| Complex karyotype | 73.5 (25/34) | 53.3 (8/15) | 20.2 (−7.9 to 48.3) | .039 |
| abn(17p) or TP53 mutations | 73.9 (17/23) | 70.0 (7/10) | 3.9 (−28.4 to 36.2) | .29 |
| Subgroups of PP population . | Treatment success: DisC, % (n/n) . | Treatment success: RIST, % (n/n) . | Difference (%) (95% CI) . | P value∗ . |
|---|---|---|---|---|
| All | 84.1 (116/138) | 81.3 (109/134) | 2.7 (−6.3 to 11.8) | .047 |
| ELN 2022 | ||||
| Favorable | 95.5 (21/22) | 100.0 (19/19) | −4.5 (−13.7 to 4.6) | .46 |
| Intermediate | 81.6 (40/49) | 83.3 (60/72) | −1.7 (−15.8 to 12.4) | .32 |
| Adverse | 82.1 (55/67) | 69.8 (30/43) | 12.3 (−3.6 to 28.2) | .016 |
| Genetic abnormality | ||||
| Mutated NPM1 | 95.5 (21/22) | 79.2 (19/24) | 16.3 (−4.2 to 36.8) | .021 |
| Mutated NPM1 and FLT3 wild type | 92.9 (13/14) | 83.3 (10/12) | 9.5 (−15.8 to 34.9) | .13 |
| FLT3-ITD | 95.8 (23/24) | 66.7 (14/21) | 29.2 (6.2 to 52.2) | .0018 |
| Secondary-type mutations† | 90.9 (20/22) | 86.4 (19/22) | 4.5 (−14.7 to 23.8) | .17 |
| Complex karyotype | 73.5 (25/34) | 53.3 (8/15) | 20.2 (−7.9 to 48.3) | .039 |
| abn(17p) or TP53 mutations | 73.9 (17/23) | 70.0 (7/10) | 3.9 (−28.4 to 36.2) | .29 |
Treatment success was defined as CR on day 56 after alloHCT. The differences in success rates between DisC and RIST have been calculated with 95% confidence intervals.
P values <.025 indicate noninferiority of DisC vs RIST with respect to a noninferiority margin of 5%.
Secondary-type mutations comprise ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and/or ZRSR2 mutations.